Veltuzumab

Source: Wikipedia, the free encyclopedia.
Veltuzumab
Humanized (from mouse)
TargetCD20
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6458H9918N1706O2026S46
Molar mass145349.06 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Veltuzumab is a

clinical trials.[3] When used with milatuzumab it showed activity.[4]

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]

In August 2015 the

immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]

See also

  • CD20 antagonist

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
  2. PMID 19710501
    .
  3. ^ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
  4. PMID 25847298
    .
  5. .
  6. ^ a b "FDA grants orphan drug designation to veltuzumab for ITP". HemOnc Today. Healio.com. August 4, 2015.